The sales of Genito Urinary System and Sex Hormones in Germany have exhibited a consistent downward trend from 2013 to 2023, decreasing from 2.5 units in 2013 to 1.3 units in 2023. Year-on-year percentage variations have largely been negative, reaching declines as significant as -9.09% in 2017 and -10% in 2018. The Compound Annual Growth Rate (CAGR) for this period demonstrates a consistent decline, with an average annual decrease of approximately -6.3% over the last five years.

Looking forward, the forecast data from 2024 to 2028 suggest a continued decline. The forecasted CAGR over the next five years is -3.29%, leading to an estimated total decline of 15.38% by 2028. This indicates that while the rate of decline may slow slightly, the downward trend will persist.

Future trends to watch for include:

Potential changes in healthcare policies or market dynamics that could influence sales.
Technological advancements leading to new treatments or alternatives.
Population demographics and aging, which may impact demand for these medications.
Economic factors that could affect consumer purchasing power and healthcare expenditure.